Search: onr:"swepub:oai:research.chalmers.se:76384845-91ae-439b-afb2-463fcc4f5bfb" >
Enabling modular do...
-
Govender, Rydvikha,1989Chalmers tekniska högskola,Chalmers University of Technology,AstraZeneca AB
(author)
Enabling modular dosage form concepts for individualized multidrug therapy: Expanding the design window for poorly water-soluble drugs
- Article/chapterEnglish2021
Publisher, publication year, extent ...
-
Elsevier BV,2021
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:research.chalmers.se:76384845-91ae-439b-afb2-463fcc4f5bfb
-
https://doi.org/10.1016/j.ijpharm.2021.120625DOI
-
https://research.chalmers.se/publication/523791URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Multidrug dosage forms (aka combination dosage forms, polypills, etc.) create value for patients through reduced pill burdens and simplified administration to improve adherence to therapy. Enhanced flexibility of multidrug dosage forms would provide further opportunities to better match emerging needs for individualized therapy. Through modular dosage form concepts, one approach to satisfy these needs is to adapt multidrug dosage forms to a wider variety of drugs, each with a variety of doses and release profiles. This study investigates and technically explores design requirements for extending the capability of modular multidrug dosage form concepts towards individualization. This builds on our recent demonstration of independent tailoring of dose and drug release, which is here extended towards poorly water-soluble drugs. The challenging design requirement of carrying higher drug loads in smaller volumes to accommodate multiple drugs at their clinical dose is here met regarding dose and release performance. With a modular concept, we demonstrate high precision (<5% RSD) in dose and release performance of individual modules containing felodipine or naproxen in Kollidon VA64 at both a wide drug loading range (5% w/w and 50% w/w drug) and a small module size (3.6 mg). In a forward-looking design-based discussion, further requirements are addressed, emphasizing that reproducible individual module performance is predictive of dosage form performance, provided the modules are designed to act independently. Therefore, efforts to incorporate progressively higher drug loads within progressively smaller module volumes will be crucial to extend the design window further towards full flexibility of future dosage forms for individualized multidrug therapy.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Abrahmsén-Alami, SusannaAstraZeneca AB
(author)
-
Folestad, StaffanAstraZeneca AB
(author)
-
Olsson, Martina,1996Chalmers tekniska högskola,Chalmers University of Technology(Swepub:cth)maolss
(author)
-
Larsson, Anette,1966Chalmers tekniska högskola,Chalmers University of Technology(Swepub:cth)anettel
(author)
-
Chalmers tekniska högskolaAstraZeneca AB
(creator_code:org_t)
Related titles
-
In:International Journal of Pharmaceutics: Elsevier BV6020378-51731873-3476
Internet link
Find in a library
To the university's database